Zerr, Inga

[["dc.bibliographiccitation.artnumber","28"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Translational Neurodegeneration"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Younas, Neelam"],["dc.contributor.author","Fernandez Flores, Leticia C."],["dc.contributor.author","Hopfner, Franziska"],["dc.contributor.author","Höglinger, Günter U."],["dc.contributor.author","Zerr, Inga"],["dc.date.accessioned","2022-06-01T09:39:43Z"],["dc.date.accessioned","2022-08-12T13:05:02Z"],["dc.date.available","2022-06-01T09:39:43Z"],["dc.date.available","2022-08-12T13:05:02Z"],["dc.date.issued","2022-05-09"],["dc.date.updated","2022-07-29T12:18:27Z"],["dc.description.abstract","Neurodegenerative diseases are a heterogeneous group of maladies, characterized by progressive loss of neurons. These diseases involve an intricate pattern of cross-talk between different types of cells to maintain specific signaling pathways. A component of such intercellular cross-talk is the exchange of various types of extracellular vesicles (EVs). Exosomes are a subset of EVs, which are increasingly being known for the role they play in the pathogenesis and progression of neurodegenerative diseases, e.g., synucleinopathies and tauopathies. The ability of the central nervous system exosomes to cross the blood–brain barrier into blood has generated enthusiasm in their study as potential biomarkers. However, the lack of standardized, efficient, and ultra-sensitive methods for the isolation and detection of brain-derived exosomes has hampered the development of effective biomarkers. Exosomes mirror heterogeneous biological changes that occur during the progression of these incurable illnesses, potentially offering a more comprehensive outlook of neurodegenerative disease diagnosis, progression and treatment. In this review, we aim to discuss the challenges and opportunities of peripheral biofluid-based brain-exosomes in the diagnosis and biomarker discovery of Alzheimer’s and Parkinson’s diseases. In the later part, we discuss the traditional and emerging methods used for the isolation of exosomes and compare their advantages and disadvantages in clinical settings."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.citation","Translational Neurodegeneration. 2022 May 09;11(1):28"],["dc.identifier.doi","10.1186/s40035-022-00301-5"],["dc.identifier.pii","301"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/108545"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/112724"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-572"],["dc.relation.eissn","2047-9158"],["dc.rights","CC BY 4.0"],["dc.rights.holder","The Author(s)"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject","Alzheimer’s disease"],["dc.subject","Central nervous system"],["dc.subject","Diagnosis"],["dc.subject","Exosomes"],["dc.subject","Blood–brain barrier"],["dc.subject","Parkinson’s disease"],["dc.title","A new paradigm for diagnosis of neurodegenerative diseases: peripheral exosomes of brain origin"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","9"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Alzheimer's Research & Therapy"],["dc.bibliographiccitation.volume","14"],["dc.contributor.author","Hermann, Peter"],["dc.contributor.author","Villar-Piqué, Anna"],["dc.contributor.author","Schmitz, Matthias"],["dc.contributor.author","Schmidt, Christian"],["dc.contributor.author","Varges, Daniela"],["dc.contributor.author","Goebel, Stefan"],["dc.contributor.author","Bunck, Timothy"],["dc.contributor.author","Lindemann, Hanna"],["dc.contributor.author","Bogner, Carla"],["dc.contributor.author","Santana, Isabel"],["dc.contributor.author","Baldeiras, Inês"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Zerr, Inga"],["dc.contributor.author","Llorens, Franc"],["dc.date.accessioned","2022-02-01T10:31:33Z"],["dc.date.accessioned","2022-08-18T12:39:24Z"],["dc.date.available","2022-02-01T10:31:33Z"],["dc.date.available","2022-08-18T12:39:24Z"],["dc.date.issued","2022-01-13"],["dc.date.updated","2022-07-29T12:17:51Z"],["dc.description.abstract","Background Lipocalin-2 is a glycoprotein that is involved in various physiological and pathophysiological processes. In the brain, it is expressed in response to vascular and other brain injury, as well as in Alzheimer’s disease in reactive microglia and astrocytes. Plasma Lipocalin-2 has been proposed as a biomarker for Alzheimer’s disease but available data is scarce and inconsistent. Thus, we evaluated plasma Lipocalin-2 in the context of Alzheimer’s disease, differential diagnoses, other biomarkers, and clinical data. Methods For this two-center case-control study, we analyzed Lipocalin-2 concentrations in plasma samples from a cohort of n  = 407 individuals. The diagnostic groups comprised Alzheimer’s disease ( n  = 74), vascular dementia ( n  = 28), other important differential diagnoses ( n  = 221), and healthy controls ( n  = 84). Main results were validated in an independent cohort with patients with Alzheimer’s disease ( n  = 19), mild cognitive impairment ( n  = 27), and healthy individuals ( n  = 28). Results Plasma Lipocalin-2 was significantly lower in Alzheimer’s disease compared to healthy controls ( p  < 0.001) and all other groups ( p  < 0.01) except for mixed dementia (vascular and Alzheimer’s pathologic changes). Areas under the curve from receiver operation characteristics for the discrimination of Alzheimer’s disease and healthy controls were 0.783 (95%CI: 0.712–0.855) in the study cohort and 0.766 (95%CI: 0.627–0.905) in the validation cohort. The area under the curve for Alzheimer’s disease versus vascular dementia was 0.778 (95%CI: 0.667–0.890) in the study cohort. In Alzheimer’s disease patients, plasma Lipocalin2 did not show significant correlation with cerebrospinal fluid biomarkers of neurodegeneration and AD-related pathology (total-tau, phosphorylated tau protein, and beta-amyloid 1-42), cognitive status (Mini Mental Status Examination scores), APOE genotype, or presence of white matter hyperintensities. Interestingly, Lipocalin 2 was lower in patients with rapid disease course compared to patients with non-rapidly progressive Alzheimer’s disease ( p  = 0.013). Conclusions Plasma Lipocalin-2 has potential as a diagnostic biomarker for Alzheimer’s disease and seems to be independent from currently employed biomarkers."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.citation","Alzheimer's Research & Therapy. 2022 Jan 13;14(1):9"],["dc.identifier.doi","10.1186/s13195-021-00955-9"],["dc.identifier.pii","955"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/98886"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/112969"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-517"],["dc.publisher","BioMed Central"],["dc.relation.eissn","1758-9193"],["dc.rights","CC BY 4.0"],["dc.rights.holder","The Author(s)"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject","Dementia"],["dc.subject","Alzheimer’s disease"],["dc.subject","Biomarker"],["dc.subject","Plasma"],["dc.subject","Lipocalin 2"],["dc.subject","Neutrophil gelatinase-associated Lipocalin"],["dc.title","Plasma Lipocalin 2 in Alzheimer’s disease: potential utility in the differential diagnosis and relationship with other biomarkers"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]